$CRMD

CorMedix Inc. (CRMD): Submission of Matters to a Vote of Security Holders

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crmd-20260623 FALSE 0001410098 0001410098 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 24, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CRMD
Neutral
medium confidence
Mentioned
$CRMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRMDNeutralLow
01

Why it matters

Governance-related proposals were partially approved (e.g., director election, advisory say-on-pay, auditor ratification) while several charter amendments were not approved, potentially shaping future corporate governance mechanics.

02

Market read

This is primarily a compliance disclosure of voting outcomes; it does not introduce new financial or strategic information.

03

What to watch

Traders may overreact to vote outcomes; the filing lacks details on why proposals failed or any immediate follow-on actions by management or dissidents.

Relevance 6/10Novelty 3/10Timing: after-hours/filing update following the June 23, 2026 annual meeting

Background

The 8-K (Item 5.07) summarizes results from CorMedix’s 2026 Annual Meeting of Stockholders held June 23, 2026.

Company-level read

Ticker impact

$CRMDNeutralMedium confidence
Context

CorMedix filed an 8-K reporting shareholder voting results on director elections and multiple charter/bylaw proposals at its June 23, 2026 annual meeting.

Expected impact

Likely limited near-term impact; any reaction would be secondary and sentiment-driven rather than fundamental.

Evidence & confidence

This is a routine post-meeting 8-K with vote tallies; it does not disclose new guidance, transactions, enforcement actions, or material financing/strategic changes.

Market effects

Minimal; governance vote outcomes are company-specific and not a sector catalyst.

Minimal; no cross-border or macro linkage indicated.

Low; no global transaction, regulatory action, or industry-wide development described.

Counterpoint

Even without operational news, failed charter amendments could signal shareholder dissatisfaction and raise the probability of future governance activism or proxy fights.

Key entities

  • CorMedix Inc.

    Nasdaq-listed company whose shareholder vote results are reported in the 8-K.

  • CBIZ CPAs P.C.

    Independent registered public accounting firm whose appointment was ratified for the fiscal year ending December 31, 2026.

Related articles

$CRMDMedAI 8/10

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

CorMedix (CRMD) reported Q2 2026 revenue of $101.9M and adjusted EBITDA of $58.7M. The company signed a commercial supply agreement for DefenCath with a large dialysis organization, covering all top U.S. providers. Full-year revenue guidance was reaffirmed at $325M-$345M, while adjusted EBITDA guidance was raised to $125M-$140M. CorMedix anticipates submitting an sNDA for REZZAYO in Q3 2026, with potential FDA action in H1 2027. The company plans to invest in commercial infrastructure for a pote

$CRMDMed

CorMedix Inc. Q2 2026 Earnings Call Summary

CorMedix reported Q2 2026 progress on DefenCath and its REZZAYO pipeline. The company secured a multi-year supply agreement covering all leading U.S. dialysis providers, maintained DefenCath utilization through the TDAPA transition, and raised 2026 adjusted EBITDA guidance to $125-$140 million. It plans a REZZAYO prophylaxis sNDA submission in Q3 2026, with FDA action expected in H1 2027.

$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

$CRMDMedAI 8/10

CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.

$CRMDHigh

CorMedix Inc. (CRMD): Results of Operations and Financial Condition

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Rais